Pfizer Hopes Chantix Sales Would Compensate For The Losses Suffered By The Company Due To Other Drugs
Date: 22nd August 2007
The effectiveness showed by the Pfizer manufactured quit smoking drug Chantix in helping smoking addicted patients around the world to quit smoking has prompted Pfizer to hope that revenues earned from Chantix would significantly compensate for the decreased sales of the Lipitor, a drug manufactured by the company to treat high cholesterol. Altogether, with the patent periods of Norvasc and Zoloft, drugs manufactured by Pfizer to treat high blood pressure and depression respectively scheduled to expire soon in the US and alongside, the generic versions of these drugs giving tough competition to the pharmaceutical company, Pfizer`s hopes rest largely on chantix.
Statistics relating to Chantix sales reveal that in 2006 the sales of the drug was 101 million but in the initial period of 2007, Chantix sales rose significantly to $362 million . Further according to the Centers for Disease Control and Prevention reveals that till June 2007, 2.5 million smokers residing in the US have opted for Chantix prescription.
However, Dean Smith, senior associate dean for administration at the School of Public Health , University of Michigan opines that if Chantix continues to show the same results, it is soon going to be labeled as a blockbuster drug and would prove tremendously money-spinning for its manufacturer Pfizer Incl.